Abstract: The subject invention relates to compounds having the structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;(b) R' is selected from unsubstituted C.sub.1 14 C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; and halo; and(c) R" is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; methyl monosubstituted with hydroxy, thiol or amino; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; amino; unsubstituted amide; unsubstituted or C.sub.1 -C.sub.3 substituted amido; halo; unsubstituted sulfoxide; unsubstituted sulfonyl; and cyano; pharmaceutical compositions containing such compounds, and the use of such compounds for preventing or treating respiratory, ocular, and/or gastrointestinal disorders.

Abstract: The subject invention relates to skin cleansing bar soap compositions comprising:(a) from about 40% to about 95% surfactant component comprising fatty acid soap and/or synthetic surfactant, such that the composition comprises:(1) from 0% to about 95% fatty acid soap;(2) from 0% to about 50% synthetic surfactant;(b) particles of absorbent gellant material, the amount of absorbent gellant material, dry weight basis, in the composition being from about 0.02% to about 5%, the absorbent gellant material having an extractable polymer content of less than about 25%;(c) from about 5% to about 35% water;(d) from 0% to about 25% moisturizer;(e) from 0% to about 15% other ingredients comprising one or more of polymeric skin feel and mildness aid, perfume, solvent, colorant, antibacterial agent, and preservative.

Abstract: Sweetener supplement compositions which provide a bioavailable source of calcium containinga) soluble calcium;b) an edible acid component comprising a mixture of citric acid and malic acid wherein said mixture has a weight ratio of citric acid to malic acid of from about 90:10 to about 10:90; andc) sugar; in which the weight ratio of the edible acid component to the soluble calcium is from about 3:1 to about 17:1; sugar comprises at least 15%, on a dry weight basis, fructose and the weight ratio of sugar to edible acid component is from about 1:1 to about 40:1.

Abstract: The present invention relates to methods and compositions for prevention or treatment of bone loss due to periodontal disease, oral osseous surgery, periodontal flap surgery, tooth extraction, dental implants, or scaling and root planing comprising topical administration, to mucosal tissues of the oral cavity, of a composition having from about 0.001% to about 0.2% ketorolac in the oral cavity.

Abstract: The present invention relates to beverage compositions containing calcium and Vitamin C, exhibiting reduced browning. The beverage compositions comprise:a) from about 50 ppm to about 2000 ppm ascorbic acid;b) from about 100 ppm to about 2,000 ppm erythorbic acid;c) From about 0.03% to about 0.19% calcium;d) a pH control system comprising an acidic buffering component, such that the pH of the composition is from about 3.1 to about 4.5;e) from 0% to about 60% of a flavoring system;f) an effective amount of a sweetening component; andg) water.

Abstract: This application relates to storage stable beverage concentrates for preparing beverages and food compositions which are nutritionally supplemented with significant levels of calcium and to a method for preparing these concentrates. The beverage concentrates have a greater than 5 fold concentration and comprise:(a) from about 0.2% to about 1.20%, by weight, solubilized calcium;(b) from about 0.7% to about 8.25%, by weight, of an acid component comprising a mixture of citric acid and malic acid wherein said mixture has a weight ratio of citric acid to malic acid of from about 5:95 to about 50:50;(c) from about 0.05% to about 1.

Abstract: The subject invention relates to methods for prevention or treatment of gingivitis or periodontitis comprising topical administration, to gingival tissues of the oral cavity, of a composition comprising a safe and effective amount of a selective histamine-2 receptor antagonist compound, and oral care compositions used therefore.

Abstract: The subject invention encompasses methods and compositions comprising N-acetylated amino acid complexes for reducing or preventing dental plaque, calculus, or gingival or periodontol diseases of the oral cavity in humans or lower animals.

Abstract: The present invention relates to the compound cyproterone acetate thioacetate (CATA) and compositions comprising CATA. The present invention further relates to methods of treating acne and/or sebaceous gland activity comprising topical application of CATA. The present invention additionally relates to methods of regulating hair growth comprising application of compositions comprising CATA.

Abstract: A microwave susceptor which includes a dielectric substrate and a dry layer of microwave active coating material overlaying at least a portion of the substrate is provided. The coating material includes a silicate binder and an active constituent and the weight ratio of the silicate to active is about 98:2 or less (i.e. less silicate). The dry layer is electrically continuous and has a surface concentration of active constituent of about 1 gram per square meter or greater. Sodium silicate is preferred as the binder and graphite is preferred as the active constituent. In addition additives such as saccharides, glycerine and plasticizers can be added to inhibit thermal shut down and to increase the flexibility of the dry layer. The susceptor can exhibit moderate heat performance or even high heating performance if desired.

Abstract: The subject invention relates to methods for regulating wrinkles in mammalian skin comprising topical application of a lysophosphatidic acid compound having the structure: ##STR1## or a cyclic derivative thereof having the structure: ##STR2## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each --X-- is independently --O-- or --S--; and --Y-- is --O-- or --CH.sub.2 --.

Abstract: The subject invention involves antitussive pharmaceutical compositions for the peroral administration of dextromethorphan, the composition being at a pH of from about 8 to about 11.

Abstract: The subject invention involves compositions, consisting essentially of the drug active 1-3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl-5-hexyn-1-one (tebufelone) at a concentration of at least about 15%, and the balance a pharmaceutically-acceptable vehicle. The vehicle is formulated such that the compositions are homogeneous liquids at 37.degree. C. and provide good solubilization of the drug active.

Abstract: The present invention relates to a composition for regulating hair growth comprising a safe and effective amount of a supernatant derived from a culture of epithelial cells which comprises a growth stimulating factor with characteristics of mitogenicity to dermal papilla cells, mitogenicity to 3T3 cells, lack of mitogenicity to epidermal cells, and a molecular weight of greater than about 3,000D; and a pharmaceutically-acceptable carrier.

Abstract: The present invnetion relates to a compositon for topical application for regulating wrinkles in mammalian skin comprising a benzofuran derivative having the structure ##STR1## wherein R.sup.1 and R.sup.2 are each independently methyl or ethyl, R.sup.3 is C.sub.1 -C.sub.4 alkyl, y is an integer from 1 to about 3 and each X is independently selected from the group consisting of Cl, Br, I, F, NO.sub.3, NO.sub.4, SO.sub.3 and SO.sub.4, and a safe and effective amount of a topical carrier.